Skip to content
  • 6,790 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started

Combined synopsis and solicitation, 8(a) set-aside

Genetic Counseling Service

NIHRFQ123456

National Institutes of Health, National Institutes of Health Olao. Testing Laboratories and Services.

Response deadline

May 31, 2024 at 5:00 PM EDT

Closed 885 days ago. Posted May 17, 2024. Scheduled to archive June 15, 2024.

Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities

Description

As published on SAM.gov.

The National Ophthalmic Disease Genotyping and Phenotyping Network (eyeGENE®) is a research venture created by the National Eye Institute (NEI), part of the National Institutes of Health (NIH). eyeGENE® aims to advance studies of eye diseases and their genetic causes by giving researchers access to DNA samples, clinical information, and patients that may meet their criteria to participate in research studies and clinical trials.

The eyeGENE® research program will require a genetic counseling service for the newest protocol, per NIH institutional guidance. The eyeGENE® program is offering whole exome sequencing (WES) and whole genome sequencing (WGS) to participants in its recruitment protocol (NIH IRB #: 001647), National Ophthalmic Genotyping and Phenotyping Network, Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases.

Genetic testing will be completed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and the results received by the eyeGENE® study team. This clinical testing may return primary results and/or results with secondary findings unrelated to a participant’s eye condition.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. May 17, 2024

    Combined synopsis and solicitation

    Due May 31, 2024 at 5:00 PM EDT. SAM.gov, notice a39f2bac9bd6471ab9e9068c535e40ce

Points of contact